Screening for the early detection of ovarian cancer
Tests for early detection, a blood test and ultrasound, are feasible on a large scale to detect cancers of the ovary, and in almost half the cases, whereas these tumors are in their early stages, according to an essay published by the specialist journal Lancet Oncology. Ovarian cancer is often described as a "silent killer" because it gives little or no symptoms in its early stages. 70% of women are diagnosed at an advanced stage of cancer, with a survival of about 20 to 30% at five years of diagnosis. However, when detected early, it is 90% curable.

Recent progress - on transvaginal ultrasound and the development of a risk score to interpret the results of a blood test tumor marker (test "CA125") suggested that mass screening was possible. Professor Ian Jacobs of London, with colleagues, launched a test to evaluate the effectiveness of both methods and ultimately their effect on mortality due to genital cancer. Participants will be tested until the end of 2012 and followed medically until the end of 2014. Early results are encouraging. Between 2001 and 2005, 202,638 postmenopausal women, aged between 50 and 70 years, the United Kingdom, were distributed by lottery in groups with testing or both methods, with either one. Another group (101,359 women) without these tests, for comparison.

According to the results, the screening program has detected most of the women who developed ovarian cancer. Nearly half of the cancers were detected in early stages (stage I / II). While only 28% of invasive cancers are detected at an early stage according to the studies, screening helped detect 48%. In total 87 cancers were detected through screening with similar results with both methods combined or ultrasound alone.


Post a Comment

Type your comments here


My Favorite Links!